Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 1255Specimen Handling 871Carboplatin 820Magnetic Resonance Spectroscopy 809Cyclophosphamide 799Cisplatin 719Nivolumab 645Paclitaxel 626Radiotherapy 565Gemcitabine 563Biopsy 532Bevacizumab 471Dexamethasone 435fludarabine 406Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 353Capecitabine 350atezolizumab 342Rituximab 329durvalumab 328Doxorubicin 314Radiosurgery 306Pemetrexed 303Drug Therapy 294Standard of Care 293Ipilimumab 288Etoposide 279Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Glutamyl Aminopeptidase × 1 year × Clear all
NCT05415527 2026-01-29

OPTIMOVA

Institut Bergonié

Phase NA Active not recruiting
25 enrolled
Gynecologic

Ovarian Neoplasms

NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT05441163 2025-06-24

ProActIF-01

Institut Curie

Phase NA Recruiting
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡